Lupin Limited (LUPIN) — Board Meeting | 5 August 2025

· NSE 🟡 Notable ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Lupin Limited reported Q1 FY2026 standalone net profit of ₹21,280.7 million, surging 139.4% YoY from ₹8,891.8 million in Q1 FY2025, driven by revenue growth to ₹57,085.9 million (36.8% YoY). Consolidated net profit reached ₹12,214.6 million (51.6% YoY increase). The company acquired UK-based Renascience Pharma Limited for ₹1,361.6 million and transferred its OTC and API R&D businesses to wholly-owned subsidiaries effective July 1, 2025.

📄 View Original Announcement (PDF)

About Lupin Limited (LUPIN)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,04,071.47 Cr P/E: 36.2

View full LUPIN stock details →

📡 Get AI alerts when LUPIN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LUPIN — Free

📊 More LUPIN filings

See all LUPIN filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LUPIN files new disclosures

Track LUPIN filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track LUPIN — Free

Free account · 2 AI queries/day